The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
We focus on a number of topic areas identified by state health policy leaders as important to population health.
The Center for Evidence-based Policy at Oregon Health & Science University is a national leader in evidence-based decision making and policy design.
Keep up with news and updates from the Milbank Memorial Fund. Get the latest from thought leaders, including Christopher F. Koller, president of the Fund.
We publish The Milbank Quarterly, as well as reports and issues briefs on topics important to population health.
A multidisciplinary journal of population health and health policy
Paul D. Cleary
Daniel M. Fox
Christopher F. Koller
2-year Impact Factor: 6.0
Journal Citation Reports® 2017 Rankings: 2/79 (Health Policy & Services); 2/94 (Health Care Sciences & Services)
5-year Impact Factor: 7.194
As one who is privileged to edit a journal as distinguished as The Milbank Quarterly, I am keenly aware that the position sits squarely on the shoulder of giants. One of those giants, David Willis—who edited the Quarterly from 1970 to 1990—died this past January. It was in his capacity as editor of what was then titled The Milbank Memorial Fund Quarterly/Health and Society where he shined the brightest. Read more
Our op-ed section features some of the best minds currently working to improve the public’s health.
Huseyin Naci, Olivier J. Wouters, Radhika Gupta, John P.A. Ioannidis
What is the clinical evidence on therapeutic agents that treat serious conditions and are eligible for Food and Drug Administration accelerated approval? This study is the first to provide a systematic evaluation of the evidence on drugs receiving this type of approval between 2000 and 2013. These drugs often quickly become part of standard treatment, despite shortcomings in their evidence base. Read more
Sarah E. Gollust, Stacy W. Gray, Deanna Alexis Carere, Barbara A. Koenig, Lisa Soleymani Lehmann, Amy L. McGuire, Richard R. Sharp, Kayte Spector-Bagdady, Na Wang, Robert C. Green, J. Scott Roberts, for the PGEN Study Group
In mid-April, 23andMe received FDA approval to sell tests for 10 genetic conditions. As the New York Times reported in May, the tests are now creating problems for insurers who have no way of knowing the results. Researchers found that the majority of consumers supported expanded access to genetic testing services and oppose additional regulation, while those who had a negative experience were less supportive of expanded availability without a medical professional. Read more
Asterie Twizeyemariya, Sophie Guy, Gareth Furber, Leonie Segal
Wan Chen Kang Graham, Marcel Bilger